Immunoconjugates for sez6l2 and methods of use
Immunoconjugates targeting SEZ6L2 address the limitations of current cancer treatments by providing reduced toxicity and enhanced therapeutic efficacy against a range of cancers through targeted antibody-drug conjugates.
WO2026117605A2PCT designated stage Publication Date: 2026-06-04IMMUNOME INC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- IMMUNOME INC
- Filing Date
- 2025-11-25
- Publication Date
- 2026-06-04
AI Technical Summary
Technical Problem
Current cancer treatments, such as cytotoxic drugs and radiotherapy, are highly toxic and indiscriminate, leading to cancer recurrence and a need for improved, targeted therapies for SEZ6L2.
Method used
Development of immunoconjugates (ADCs) that specifically target SEZ6L2, comprising antibodies with defined CDR sequences and drug moieties, reducing toxicity and enhancing therapeutic efficacy.
Benefits of technology
The immunoconjugates provide targeted cancer therapy with reduced toxicity and improved efficacy against various cancer types, including multiple myeloma, leukemia, and solid tumors, while minimizing off-target effects.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025057136_04062026_PF_FP_ABST
Abstract
Provided herein are anti-SEZ6L2 immunoconjugates that can be used for treating cancer.
Need to check novelty before this filing date? Find Prior Art